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Aims: The present study aimed to investigate the intraplantar (ipl) and central (icv) effects of neuropeptide S
(NPS) in the formalin test and to evaluate the role of adenosine receptors, mainly A1 and A2A, in mediating
such effects.
Main methods: The ipl injection of formalin was used to assess the nociceptive activity. Moreover, by pretreating
mice with non-selective and selective antagonists of adenosine receptors, the effects of icv NPS on formalin-
induced ongoing nociception were assessed.
Key ﬁndings:Morphine-induced antinociceptive effects were observed during phases 1 and 2 of the test, while
indomethacinwas active only at the later nociceptive phase. The ipl injection ofNPS (alone or combinedwith for-
malin) did not modify the nociceptive response. However, icv NPS signiﬁcantly reduced formalin-induced
nociception during both phases. Caffeine (3mg/kg, ip), a non-selective adenosine receptor antagonist, prevented
NPS-induced antinociceptive effects. Similar to caffeine, icv ZM241385 (0.01 nmol), an A2A receptor antagonist,
prevented the antinociceptive effects of NPS. Moreover, icv DPCPX (0.001 nmol), an A1 receptor antagonist,
blocked the effects of NPS only during phase 1.
Signiﬁcance: The above ﬁndings suggest that: (i) NPS evokes central antinociceptive effects by activating both A1
and A2A receptors during phase 1, but (ii) only the adenosine A2A receptor during phase 2 of the formalin test.© 2014 Elsevier Inc. All rights reserved.Introduction
Pain is a symptom of many clinical disorders that affect a large pop-
ulation of humans, and the relief of pain is mainly achieved with phar-
macological agents. In humans, the treatment of pain commonly
employs nonsteroidal anti-inﬂammatory drugs and opioids, despite
the well-known adverse effects of these drugs, such as gastric ulcers,
nephrotoxicity, and abuse liability [3,36]. Safer andmore effective anal-
gesic drugs are a major focus in current pharmaceutical research.
A new target for the development of innovative analgesic drugs is
the peptidergic systemof neuropeptide S (NPS). NPS is an eicosapeptide
that is named due to the presence of a serine residue in its amino-y Laboratory, Department of
Grande do Norte, Av. Senador
Natal 59072-970, RN, Brazil.terminal portion [39]. The NPS peptide binds to NPSR, a typical 7-
transmembrane domain G protein-coupled receptor [39]. Studies
using CHO and HEK293 cell lines expressing recombinant NPSR showed
an intracellular increase in the concentrations of Ca+2, cAMP and phos-
phorylated MAPK in response to NPS, suggesting that NPSR can be
coupled with Gq and Gs [28,39].
The NPS precursor mRNA is expressed in areas restricted to the cen-
tral nervous system, such as the sensory trigeminal nucleus and lateral
parabrachial nucleus (neighbor to the locus coeruleus; [38]). The latter
area has been involved in the regulation of autonomic functions and no-
ciceptive processing. In fact, visceral afferent input from the nucleus of
the solitary tract [14] and pain stimuli from the spinal cord [12] are con-
ducted to the forebrain through neurons from the lateral parabrachial
nucleus. The lateral parabrachial nucleus has been reported to send
neuronal projections to many areas where NPSR mRNA is highly
expressed, including the ventromedial and paraventricular hypotha-
lamic nuclei, amygdala, and periaqueductal gray [12]. In addition,
NPSR mRNA is highly expressed in the cerebral cortex, thalamus, hypo-
thalamus and amygdala [38,39]. This pattern of NPSR distribution in the
brain suggests the involvement of the peptidergic system in the
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9A.D. Victor Holanda et al. / Life Sciences 120 (2015) 8–12regulation of various biological functions, including locomotion, anxi-
ety, arousal and wakefulness, food intake, drug reward, memory pro-
cessing, and nociceptive transmission. For a review of all the biological
actions modulated by this peptidergic system see Guerrini et al. [13].
Despite the fact that intracerebroventricular (icv) administration of
NPS evokes antinociception [21,26], little is known about the mecha-
nisms by which the activation of NPSR receptor signaling induces pain
relief. In this work we investigated the effects of NPS on formalin-
induced nociceptive behaviors. In addition, we studied the involvement
of adenosine A1 and A2A receptors in the antinociceptive actions of NPS.Fig. 1. Effects of standard analgesic drugs, indomethacin (10 mg/kg, ip) and morphine (5
mg/kg, ip) in the ﬁrst (0–5 min) and second phases (15–30 min) of ongoing nociception
induced by1% formalin (20 μl/paw). Each bar represents themean±S.E.M. of 5–6 animals
(ANOVA, Student–Newman–Keuls test, *P b 0.05 vs. control; phase 1: F(2,14) = 23.76,
phase 2: F(2,14) = 8.46).Material and methods
Animals
Male Swiss mice weighing 28–35 g from our own breeding stock
were housed in groups of 10–12 per cage (33 cm × 40 cm × 17 cm)
with food and water ad libitum. Animals were kept under controlled
temperature (23 ± 2 ºC) and a 12-h light/dark cycle (lights on at
06:00). All experiments were conducted in accordance with Brazilian
law no. 11.794/2008 for the experimental use of animals. The protocol
was approved by the Ethic Committee for Animal Use of Federal Univer-
sity of Rio Grande do Norte (Protocol no. 012/2011). This study is re-
ported following the ARRIVE guidelines [17].Drugs
Human NPS was synthesized by Dr. Guerrini (Department of Chem-
istry and Pharmaceutical Sciences, University of Ferrara, Ferrara, Italy)
and was solubilized in saline (NaCl 0.9%). Indomethacin (a non-
steroidal anti-inﬂammatory drug), caffeine (nonselective A1 and A2A re-
ceptor antagonist), DPCPX (1,3-dipropyl-8-cyclopentylxanthine; selec-
tive A1 receptor antagonist) and ZM241385 (4-(−2-[7-amino-2-{2-
furyl}{1,2,4}triazolo{2,3-a}{1,3,5}triazin-5-yl-amino]ethyl)phenol; se-
lective A2A receptor antagonist) were all purchased from Sigma-
Aldrich (San Louis, MO, USA). Caffeine was dissolved in saline solution.
The stock solutions of DCPX, ZM241385 and indomethacin were pre-
pared in 100% dimethylsulfoxide (DMSO), stored at −4 °C, and dis-
solved in saline solution just before the experiments. The ﬁnal
concentration of DMSO in DPCPX and ZM241385 solutions did not ex-
ceed 0.1%, while the indomethacin solution contained 8.3% DMSO. The
concentration of DMSO did not cause any detectable effect per se. Mor-
phine (Hipolabor Farmaceutica Ltda., Sabará, MG, Brazil), an opioid an-
algesic drug, was dissolved in saline solution.Phase 1 Phase 2
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Fig. 2. Effects of NPS administration into the lateral ventricle (0.1 nmol) and the hind paw
(10 nmol) in the ﬁrst (0–5 min) and second phases (15–30 min) of ongoing nociception
induced by 1% formalin (20 μl/paw). Each bar represents the mean ± S.E.M. of 6 animals.
(ANOVA, Student–Newman–Keuls test, *P b 0.05 vs. control; phase 1: F(2,16) = 19.56,
phase 2: F(2,16) = 12.69).Treatments
Twenty microliters of 1% formalin was injected subcutaneously into
the plantar surface (intraplantar administration, ipl) of the right hind
paw of mice. The effects of indomethacin (10 mg/kg, ip) and morphine
(5 mg/kg, sc) were evaluated by injecting the drugs 30 min before
formalin.
To evaluate the possible effects of NPS on nociceptive
responses induced by formalin, the peptide was injected either
intracerebroventricularly (icv, 0.1 nmol, 5 min pretreatment) or
intraplantarly (10 nmol/20 μl, co-injected with formalin). Icv NPS was
injected at a rate of 2 μl/min in a total volume of 2 μl. The icv dose of
NPS used herein was previously shown to evoke antinociceptive effects
[26]. To investigate the involvement of adenosine A1 and A2A receptors
on the antinociceptive effects of NPS in the formalin test, caffeine (3mg/
kg) was injected intraperitoneally (ip), in a volume of 10 ml/kg, 15 min
before formalin. In another subset of animals, DPCPX (0.001 nmol; 1 μl,
icv) or ZM241385 (0.01 nmol; 1 μl, icv) was given 10 min before
formalin.Cannula implantation in the lateral ventricle
All icv injections were performed by a 22-G guide cannula perma-
nently implanted into the lateral ventricle. Surgical implantation of a
stainless steel cannula into the lateral ventricle was conducted accord-
ing to our previous studies [7]. Brieﬂy, mice were anesthetized with a
ketamine/xylazine solution (100 mg/kg and 10 mg/kg, ip, respectively)
and placed in a stereotaxic apparatus. A vertical incision was made in
the skin to expose the skull. A stainless steel guide cannula was im-
planted into the lateral ventricle and was ﬁxed with dental cement. Co-
ordinates toward the bregmawere ML+1.1 mm, AP−0.6 mm and DV
−1.0 mm [25]. To prevent occlusion, a dummy cannula was inserted
into the guide cannula. The dummy cannula protruded 1 mm from the
guide cannula. After surgery, the animals were allowed to recover for
at least 3 days.
Formalin test
The procedure was performed as previously described by Hunskaar
and Hole [16]. The animals were acclimatized in the laboratory for at
least 2 h before testing and then individually placed in a glass cone
(20 cm in diameter) for 20min. After the acclimatization period, forma-
lin was ipl injected in the right hind paw of themice. Immediately after
the formalin injection, animals were put back into the glass cone and
were observed for 30 min. A mirror was placed behind the glass cone
to allow an unobstructed view of the formalin injected paw. The time
(s) that animals spent licking, shaking and retracting the injected paw
was timed with a chronometer and was considered to be indicative of
ongoing nociception. The intraplantar formalin injection produced a
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Fig. 3. Effect of pretreatment with caffeine (3 mg/kg, ip) on the antinociceptive actions of
NPS (0.1 nmol, icv) in the ﬁrst (0–5 min) and second phases (15–30 min) of ongoing
nociception induced by 1% formalin (20 μl/paw). Each bar represents the mean ± S.E.M.
of 6–8 animals. (ANOVA, Student–Newman–Keuls test, *P b 0.05 vs. control; #P b 0.05
vs. NPS; phase 1: F(3,25) = 14.26, phase 2: F(3,25) = 23.10).
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Fig. 5. Effect of pretreatment with ZM241385 (0.01 nmol, icv) on the antinociceptive ac-
tions of NPS (0.1 nmol, icv) in the ﬁrst (0–5 min) and second phases (15–30 min) of on-
going nociception induced by 1% formalin (20 μl/paw). Each bar represents the mean ±
S.E.M. of 6–8 animals. (ANOVA, Student–Newman–Keuls test, *P b 0.05 vs. control,
#P b 0.05 vs. NPS; phase 1: P b 0.0001; F(3,28)=14.19; phase 2: P b 0.0001, F(3,28)= 70.73).
10 A.D. Victor Holanda et al. / Life Sciences 120 (2015) 8–12biphasic nociceptive response: (I) an acute phase of short duration
followed by (II) a longer lasting tonic phase. Hence, the evaluation of
the nociceptive behavior was divided into two phases. The ﬁrst 5 min
after formalin injectionwas known as the ﬁrst phase, followed by a qui-
escent period of approximately 10 min, and then the second phase oc-
curred from 15 to 30 min after this period.Histology
After completing the test, mice were euthanized with sodium
thiopental (N100 mg/kg, ip) and injected icv with methylene blue
dye (2 μl). Mice were perfused with saline solution and their brains
were removed to verify the placement of the guide cannula. Only
the data from those animals with dispersion of the dye throughout
the ventricles were used for statistical analysis (these were ap-
proximately 95% of cannula implanted animals).Statistical analysis
The data presented herein were reported as mean ± S.E.M. Results
were submitted to Levene's test for homogeneity of variance and to Kol-
mogorov–Sminorv's test for normality. Treated and control groupswere
compared using one-way ANOVA followed by the Student–Newman–
Keuls test. A value of P b 0.05 was considered to be signiﬁcant. These
analyses were performed by GraphPad InStat software, version 3.06
(La Jolla, CA, USA) and Statistica, version 5.1 (Tulsa, OK, USA).0
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Fig. 4. Effects of pretreatmentwith DPCPX (0.001 nmol, icv) on the antinociceptive actions
of NPS (0.1 nmol, icv) in the ﬁrst (0–5 min) and second phases (15–30 min) of ongoing
nociception induced by 1% formalin (20 μl/paw). Each bar represents the mean ± S.E.M.
of 6–8 animals. (ANOVA, Student–Newman–Keuls test, *P b 0.05 vs. control, #P b 0.05 vs.
NPS; phase 1: F(3,26) = 55.09; phase 2: F(3,26) = 239.13).Results
Effects of standard antinociceptive drugs in the formalin test
Fig. 1 illustrates the effects of standard analgesic drugs, indometha-
cin and morphine on ongoing nociception induced by ipl formalin. Ani-
mals injected with formalin displayed a typical biphasic nociceptive
response. Mice spent approximately 150 s displaying nociceptive be-
haviors during the ﬁrst 5 min of the assay (phase 1), and approximately
200 s during the period of 15–30 min (phase 2). Pretreatment with
morphine (5mg/kg, sc) signiﬁcantly attenuated the nociceptive behav-
ior time in both phases of the formalin test. The inhibitory effect exerted
by the alkaloid amounted to 50% and 40% of the control for phases 1 and
2, respectively (Fig. 1). Moreover, animals treated with indomethacin
(10 mg/kg, ip) displayed a statistically signiﬁcant reduction of nocicep-
tive behavior only during phase 2. The inhibitory effect of indomethacin
was 67% of control values (Fig. 1).Effects of NPS in the formalin test
Ipl NPS (10 nmol/20 μl/paw) did not evoke any nociceptive behavior
inmice observed during 5min (data not shown). Additionally,when co-
injected ipl with formalin, NPS did not affect the nociceptive behavior
time during phases 1 and 2 of the test (Fig. 2). However, supraspinal ad-
ministration of NPS decreased the ongoing nociception time by 39% in
phase 1 and by 55% in phase 2 (Fig. 2) compared to control values.Effects of adenosine antagonists on the antinociceptive actions of NPS in the
formalin test
Fig. 3 illustrates the effects of systemic pretreatmentwith caffeine on
mice icv injected with NPS in the formalin test. Pretreatment with caf-
feine did not modify phase 1 or 2 of formalin-induced nociception
(Fig. 3). However, ip caffeine fully prevented the antinociceptive effects
of NPS in phase 1 and attenuated the antinociceptive actions of the pep-
tide in phase 2 (Fig. 3).
Fig. 4 shows the actions of icv DPCPX on the antinociceptive effects of
NPS in the formalin test. The administration of DPCPXdid not change the
nociceptive behavior time induced by formalin in both phases (Fig. 4).
Interestingly, DPCPX prevented the antinociceptive effects of NPS during
phase 1, but not during phase 2 of the formalin test (Fig. 4).
The effects of the icv pretreatment with ZM241385 in mice
supraspinally treatedwithNPS are depicted in Fig. 5. The administration
of ZM241385 did not change the ongoing nociception induced by for-
malin (Fig. 5). However, icv ZM241385 signiﬁcantly attenuated the
antinociceptive effects of NPS during phases 1 and 2 of the formalin
test (Fig. 5).
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This study reinforces the antinociceptive action of NPS in themouse
formalin test and, for the ﬁrst time, indicates that systemic administra-
tion of caffeine (non-selective A1/A2A receptor antagonist) and central
injections of DPCPX (selective A1 receptor antagonist) and ZM241385
(selective A2A receptor antagonist) inhibit antinociception induced by
icv NPS, thus supporting a role for central A1 and A2A receptors in medi-
ating NPS-induced pain relief.
The formalin test is among themost commonly used analgesiometric
assays [11,37]. As nicely summarized by Barrot [1], the formalin injection
produces a biphasic behavioral reaction with an initial phase within the
ﬁrst minutes post-injection followed by a quiescent period (approxi-
mately 10 min) and a second phase of nociceptive behaviors lasting
20–40 min. Phase 1 is related to the direct stimulation of nociceptors
and is sensitive to local anesthetics and opiates, while phase 2 involves
both inﬂammatorymechanisms and central sensitizationwithin the dor-
sal horn [37]. Phase 2 responds to various drugs with established clinical
analgesic action, such as opiates [11], steroidal or non-steroidal anti-
inﬂammatory drug analgesics [16], N-methyl-D-aspartate antagonists
[6], and gabapentin [34].
To validate our experimental conditions, the effects ofmorphine and
indomethacin were assessed in mice ipl injected with formalin. In line
with published ﬁndings, the present results showed that the systemic
administration of morphine attenuated both nociceptive phases of the
formalin test, while indomethacin reduced formalin-induced enduring
nociception only during phase 2 of the test [15,16].
Similar to morphine, icv NPS reduced formalin-induced nociceptive
behaviors in both phases of the test. The antinociceptive effects of icv
NPS were observed at the same dose as previously described in mice
by Peng et al. [26] in the formalin test, and by Li et al. [21] in the tail
withdrawal and the hot-plate tests. Recently, Zhang et al. [43] showed
that exogenous NPS (1 nmol) attenuated thermal hyperalgesia andme-
chanical allodynia in chronic constriction sciatic nerve injury in rats.
In contrast, the ipl administration of NPS was not able to modify the
response to formalin. Interestingly, NPS immunoreactive cells are found
in the skin, skin appendages and immune cells including splenic lym-
phocytes and pulmonary alveolar macrophages in pigs [40,41]. Regard-
ing the NPSR, it is also expressed in the skin and immune cells, i.e.
macrophages, neutrophils, and intraepithelial lymphocytes [27,35]. A
growing body of in vitro and in vivo assays suggest a proinﬂammatory
proﬁle of action for NPS [27,41,42]. Although some ﬁndings support a
role for NPS in inﬂammation, the present data suggests that the activa-
tion of NPSR in the periphery does not affect nociceptive transmission.
The present ﬁndings showed that the systemic treatment with caf-
feine prevented the antinociceptive effects of NPS during both phases
of the formalin test. A similar pattern was found when mice were
supraspinally treated with the selective A2A receptor antagonist
ZM241385. Our ﬁndings also demonstrated that A1 receptor signaling
is involved only on the actions of NPS during phase 1 of the formalin
test.
The mechanism by which NPS evokes central antinociceptive effects
is still unknown. However, NPSR antagonists, which are inactive in no-
ciceptive animal models, prevent NPS-induced antinociceptive effects
[21,26]. No behavioral differences between NPSR knockout and wild-
type mice were found in the formalin test [33]. The inactivity of NPSR
antagonists in animal models of pain and the absence of a nociceptive
phenotype in NPSR knockout mice strongly suggest that NPSergic path-
ways do not tonically modulate pain transmission.
Regarding the involvement of other neurotransmitter systems on
the antinociceptive effects of NPS, Peng et al. [26] showed that the
systemic administration of naloxone, a non-selective opioid receptor
antagonist, failed to inhibit the antinociceptive effects of NPS
suggesting that NPS-induced antinociception does not engage
opioidergic pathways. A growing body of evidence suggests the
participation of adenosinergic signaling in NPS-induced biologicalactions. First, Lage et al. [18], using PCR experiments, showed alter-
ations inmRNA transcript levels of NPS and NPSR in the rat hypothal-
amus and brainstem after acute and repeated caffeine treatments.
Second, our research group has demonstrated inhibitory effects of
caffeine and ZM241385 on NPS-induced hyperlocomotion [2].
Third, extracellular adenosine seems to mediate NPS-induced
hyperlocomotion because the inhibition of ecto-5′-nucleotidase
prevented the psychostimulant actions of NPS [24]. In addition, an
Asn(107)Ile NPSR polymorphism has been described in humans.
This polymorphism has functional consequences; NPS is approxi-
mately 10-fold more potent at the Ile107 than at the Asn107 NPSR
([28]). A recent study in humans investigated the impact of the
NPSR Asn(107)Ile polymorphism on affect-modulated startle
response [10]. The authors observed that Ile107 NPSR carriers
showed an increased startle magnitude in response to neutral stim-
uli, while a decreased startle magnitude was observed in response
to unpleasant stimuli in those subjects when they ingested caffeine.
Altogether, these ﬁndings support a clear interplay between NPS and
adenosinergic systems in modulating different biological functions.
No information is available about the nociceptive effects of selec-
tive adenosine receptor antagonists when supraspinally injected in
rodents. In this study, we observed that at the doses tested, the selec-
tive antagonists DPCPX and ZM241385 did not affect mouse behavior
in the formalin test. Regarding caffeine, in the present study no alter-
ations in nociceptive behaviors were observed in mice systemically
treated with this non selective adenosine antagonist. This observa-
tion is in line with previous literature data for rodents in the formalin
test [9,22].
As far as the localization of NPSR and adenosine receptormodulating
pain transmission is concerned, some information is present in the liter-
ature. Recently, an electrophysiological study showed that NPS controls
amygdala output and pain-related affective behaviors through a direct
activation of inhibitory intercalated neurons. Additionally, Peng et al.
[26] showed an increase in c-Fos protein expression in the
periaqueductal gray in formalin-injected mice after icv NPS. Some evi-
dence of the expression of A1 receptors and A2A receptors in these
brain areas are reported in the literature [8,23,29,31]. However, focused
immunohistochemical studies are required for reinforcing these hy-
potheses. The involvement of other brain areas (e.g., thalamic nuclei;
[20,38]) cannot be ruled out in considering the interaction between
adenosine and NPS in controlling pain transmission.
The results of analgesiometric assays can be biased by the effect of
drugs on locomotor behavior. It is widely reported that NPS produces
psychostimulant effects [4,5,19,30,32,39]. However, we have previously
demonstrated that 0.1 nmol of NPS, the dose used in the present study,
does not modify locomotor activity in mice [7]. This ﬁnding suggests
that the inhibitory effect exerted by NPS in the formalin test is indeed
a genuine antinociceptive action. The same can be said for the action
of caffeine. In fact, the alkaloid at the dose employed in the present
study does not affect locomotion inmice [2]. No information is available
about the central effects of DPCPX and ZM241385 on spontaneous loco-
motion. However, no alteration in animal gross behavior, such as agita-
tion or increased ambulation into the cylinder cone, was noticed during
the formalin test in animals treated with these antagonists. Collectively,
these observations suggest that neither NPS nor adenosine antagonists,
alone or combined, affect mouse locomotion at the doses used herein.
Conclusion
Our data revealed that icv but not ipl NPS signiﬁcantly inhibited both
phases of formalin-induced nociceptive behaviors. Moreover, receptor
antagonist studies demonstrate the involvement of adenosine in the
antinociceptive effects of NPS. In particular, both A1 and A2A receptors
seem to be involved in the action of NPS on phase 1 of the formalin test,
while only A2A receptors contribute to the NPS-induced antinociceptive
actions during phase 2 of the assay.
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